--- a
+++ b/clusters/9knumclustersv2/clust_1142.txt
@@ -0,0 +1,30 @@
+Stage II, III or IV disease as defined by the Ann Arbor Staging System
+Ann Arbor stage II-IV disease (Stage I primary mediastinal B-cell lymphoma will also be eligible)
+Histologically confirmed CD-positive, CD-positive untreated primary mediastinal B-cell lymphoma (any Ann Arbor stage), diffuse large B-cell lymphoma (Ann Arbor stage III or IV), or grey zone lymphoma (any Ann Arbor stage); patients with heterogeneous, weak or equivocal CD staining will also be included (no specific cut off percentage for CD stain is required)
+Stages II, III, or IV (Ann Arbor Staging)
+NHL (Part  and ): Intermediate or high risk by Ann Arbor Staging with Cotswald Modifications that meets criteria for active disease requiring therapy.
+Ann Arbor stage II-IV
+Patients with histologically-confirmed Low Tumor Burden Follicular Lymphoma, without B symptoms, Ann Arbor stage II to IVA NHL (CD+ FL of Grades , , or a)
+Ann Arbor stage I - stage IV DLBCL at the time of relapsed/refractory disease to be eligible
+Ann Arbor stage I or II disease
+Ann Arbor Stage II, III or IV
+At least one adverse prognostic factor: \r\n* Initial relapse =<  months after primary chemotherapy\r\n* Staged as Ann Arbor classification initial stage III or IV disease\r\n* Chemotherapy resistant disease\r\n* Failure to achieve a complete response (CR) with cytoreductive chemotherapy or persistent positive fludeoxyglucose F  (FDG)-positron emission tomography (PET) imaging
+Patients must have non-bulky stage I or II disease by Ann Arbor classification\r\n* This staging excludes fludeoxyglucose F  (FDG)-PET evaluation\r\n* Patients who have stage I or II non-bulky disease based on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible\r\n* Stage and bulk are assigned using measurements obtained prior to biopsy
+Collection of a  ml blood sample (red top for serum) from the patient for Ann Arbor Scoring and ready to be shipped immediately after randomization.
+Stages II bulky disease (defined as mass size of more than  cm), stage III, or IV (Ann Arbor staging); patients with stage I and stage II non-bulky disease are excluded from this study
+Ann Arbor stage II to IV.
+Ann Arbor stage  or  or stage  with bulky disease
+Stage III/IV disease by Ann Arbor Staging
+Ann Arbor stage IIB, IIIB, IVA, or IVB
+Stage II (not candidates for local x-ray therapy), III, or IV disease by the Ann Arbor Classification
+Information available for calculation of International Prognostic Score (IPS): age, gender; albumin, white blood cell (WBC) count, hemoglobin, lymphocyte count, and stage of disease according to Ann Arbor classification
+Stage II, III, and IV disease by Ann Arbor classification
+Ann Arbor Stage I disease
+Histologically confirmed diagnosis of follicular lymphoma CD+ (Grade ,  or a) Ann Arbor Stage II, III or IV disease.
+Stage III or IV disease at any time in the past (Ann Arbor Staging System for Non-Hodgkins Lymphomas)
+Ann Arbor Stage II, III, or IV
+Stage must be classified as one of the following:\r\n* Ann Arbor stage IA or IIA with:\r\n** Non-bulky mediastinal disease (< % mediastinal to thoracic ratio on chest x-ray [CXR])\r\n** <  nodal regions involved on the same side of the diaphragm\r\n** No E lesion
+Stage II, III or IV (Ann Arbor Staging)
+Ann Arbor stage I disease.
+Ann Arbor stage III or IV disease at diagnosis or at relapse/refractory disease confirmation
+Ann Arbor stage III or IV disease (Cohort A only)